Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

This study has been terminated.
(Refer to Detailed Description for documentaion of Termination Statement.)
Information provided by (Responsible Party):
Pfizer Identifier:
First received: May 2, 2011
Last updated: November 4, 2015
Last verified: November 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: November 2015
  Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)